Vivos Therapeutics Inc (VVOS) Stock Price, Quote & News

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test...

Industry: Medical Devices

Sector: Healthcare

Phone: 866 908 4867

Website: www.vivos.com

Address:

7921 Southpark Plaza, Suite 210, Littleton, United States

Loopi Jun. 6 at 10:18 AM

$VVOS Zero cash better to know that plus delusional. I don’t follow optimistic voices once you do very miss up your account. Be aware many people here you think are talking positive no their average is $4 believe me. Play with pumps, leave the first stop 🛑

0 · Reply

kemsma62 Jun. 6 at 9:40 AM

$VVOS After a long period of decline, the stock is finally coming to life and attracting renewed investor interest.

0 · Reply

stockpicker12e Jun. 6 at 9:05 AM

$VVOS They have the financing with big investors who will never let Vivos go under. Only lying shorts can hurt vivos but only temporary because they lie and the truth ulitmatey comes out and this stock is going to 100

0 · Reply

stockpicker12e Jun. 6 at 9:04 AM

$VVOS Shorts lie, saying other devices out there. Not even close> ✔️ “Fixes the airway long‑term” → No other device matches Vivos. It is the only FDA‑cleared system designed to expand the airway and potentially reduce or eliminate OSA.

0 · Reply

stockpicker12e Jun. 6 at 9:00 AM

$VVOS CPAP or CCRAP or Inspire both not as good as VIVOS Vivos Non‑invasive No surgical complications Lower risk of infection or device failure Inspire Requires surgery and recovery Risks include infection, hardware malfunction, need for reprogramming

0 · Reply

stockpicker12e Jun. 6 at 8:56 AM

$VVOS They have the bridge to cash flow positive. This is going to 100 dollars in time. This is like invisalign and better than inspire.

0 · Reply

Jerseyguy856 Jun. 6 at 2:55 AM

$VVOS left some on the table but made this in 1 min so cant complain

0 · Reply

skips200k Jun. 6 at 2:03 AM

$VVOS looking better. A few more strategic deals should do it. I think there's more in the works than we know. Glta.

0 · Reply

STACKD0E Jun. 6 at 1:12 AM

$ALL $VVOS

0 · Reply

ka1954 Jun. 5 at 10:49 PM

$VVOS why the after hours fuckery? we all know this is done for the near future

0 · Reply

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

2026-05-20T20:22:09.000Z - 16 days ago

Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)

May 20, 2026, 4:10 PM EDT - 16 days ago

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

May 20, 2026, 4:00 PM EDT - 16 days ago

Vivos Therapeutics Quarterly report: Q1 2026

May 20, 2026, 4:00 PM EDT - 16 days ago

Vivos Therapeutics Earnings release: Q1 2026

May 9, 2026, 11:53 AM EDT - 27 days ago

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

ACTU ATAI

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Vivos Therapeutics Registration statement: Registration filing

2026-04-17T13:52:17.000Z - 7 weeks ago

Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright

2026-04-17T12:43:47.000Z - 7 weeks ago

Vivos Therapeutics price target lowered to $1.75 from $2.50 at Alliance Global

Apr 15, 2026, 5:00 PM EDT - 7 weeks ago

Vivos Therapeutics Earnings Call Transcript: Q4 2025

Apr 15, 2026, 5:00 PM EDT - 7 weeks ago

Vivos Therapeutics Earnings release: Q4 2025

Apr 15, 2026, 5:00 PM EDT - 7 weeks ago

Vivos Therapeutics Annual report: Q4 2025

Apr 15, 2026, 4:20 PM EDT - 7 weeks ago

Vivos Therapeutics Reports Full Year 2025 Financial Results

Apr 15, 2026, 8:45 AM EDT - 7 weeks ago

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

Apr 7, 2026, 8:45 AM EDT - 2 months ago

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Mar 26, 2026, 8:45 AM EDT - 2 months ago

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

2026-03-17T13:00:18.000Z - 2 months ago

Vivos Therapeutics’ oral medical devices proven to enhance airways

Mar 17, 2026, 8:45 AM EDT - 2 months ago

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Feb 17, 2026, 7:00 AM EST - 3 months ago

Vivos Therapeutics Registration statement: Registration Filing

2026-02-17T11:15:45.000Z - 3 months ago

Vivos Therapeutics files to sell 3.96M shares of common stock for holders

2026-02-05T13:50:40.000Z - 4 months ago

Vivos, SoundHealth collaborate to expand access to SoundHealth’s technology

2026-02-05T13:50:12.000Z - 4 months ago

Vivos Therapeutics signs 12-part media series with New to the Street

Feb 5, 2026, 8:45 AM EST - 4 months ago

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Jan 20, 2026, 5:31 PM EST - 4 months ago

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

2026-01-16T13:10:49.000Z - 5 months ago

Vivos Therapeutics announces exercise of warrants for $4.64M gross proceeds

Jan 16, 2026, 8:00 AM EST - 5 months ago

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

Dec 16, 2025, 11:00 AM EST - 6 months ago

Vivos Therapeutics Transcript: Fireside Chat

2025-12-16T13:50:29.000Z - 6 months ago

Vivos Therapeutics opens sleep center in Auburn Hills, Michigan

Dec 16, 2025, 8:45 AM EST - 6 months ago

Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

Nov 19, 2025, 5:00 PM EST - 7 months ago

Vivos Therapeutics Earnings Call Transcript: Q3 2025

Nov 19, 2025, 5:00 PM EST - 7 months ago

Vivos Therapeutics Earnings release: Q3 2025

Nov 19, 2025, 5:00 PM EST - 7 months ago

Vivos Therapeutics Quarterly report: Q3 2025

2025-11-19T21:30:18.000Z - 7 months ago

Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

Nov 19, 2025, 4:20 PM EST - 7 months ago

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Nov 19, 2025, 8:30 AM EST - 7 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

2025-11-17T11:15:44.000Z - 7 months ago

Vivos Therapeutics initiated with a Buy at H.C. Wainwright

2025-09-30T12:45:33.000Z - 8 months ago

Vivos Therapeutics announces additional data from use of Vivos DNA device

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

Sep 29, 2025, 8:00 AM EDT - 8 months ago

Vivos Therapeutics Proxy statement: Proxy Filing

2025-09-17T12:41:24.000Z - 9 months ago

Vivos Therapeutics announces trial results in pediatric OSA treatment

Sep 17, 2025, 8:30 AM EDT - 9 months ago

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

Sep 5, 2025, 8:00 AM EDT - 9 months ago

Vivos Therapeutics Registration statement: Registration Filing

Aug 19, 2025, 5:00 PM EDT - 10 months ago

Vivos Therapeutics Earnings Call Transcript: Q2 2025

Aug 19, 2025, 5:00 PM EDT - 10 months ago

Vivos Therapeutics Earnings release: Q2 2025

Aug 19, 2025, 5:00 PM EDT - 10 months ago

Vivos Therapeutics Quarterly report: Q2 2025

Aug 19, 2025, 4:20 PM EDT - 10 months ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 19, 2025, 8:30 AM EDT - 10 months ago

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

2025-07-30T12:50:50.000Z - 11 months ago

Vivos Therapeutics appoints Bruhn as EVP, Jones as SVP

2025-07-01T12:40:14.000Z - 1 year ago

Vivos Therapeutics receives Medicare approval for VidaSleep Oral Applicance

2025-06-26T12:40:25.000Z - 1 year ago

Vivos announces results published of OSA using Daytime-Nighttime Appliance

Jun 26, 2025, 8:30 AM EDT - 1 year ago

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

2025-06-11T12:35:17.000Z - 1 year ago

Vivos Therapeutics completes acquisition of SCN for $6M in cash, $1.5M in stock

2025-05-20T11:05:21.000Z - 1 year ago

Vivos Therapeutics downgraded to Neutral from Buy at Alliance Global Partners

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings release: Q1 2025

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Quarterly report: Q1 2025

May 14, 2025, 9:15 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

2025-04-16T12:36:59.000Z - 1 year ago

Vivos Therapeutics announces agreement to acquire operating assets of SCN

Apr 16, 2025, 8:30 AM EDT - 1 year ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

2025-04-01T13:26:00.000Z - 1 year ago

Vivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global Partners

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings release: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Annual report: Q4 2024

Mar 31, 2025, 4:20 PM EDT - 1 year ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Feb 18, 2025, 12:00 PM EST - 1 year ago

Vivos Therapeutics Transcript: Fireside Chat

Feb 11, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Jan 29, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Jan 22, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Dec 23, 2024, 8:00 AM EST - 1 year ago

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Nov 6, 2024, 7:00 AM EST - 1 year ago

Vivos Therapeutics Proxy statement: Proxy Filing

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Vivos Therapeutics Proxy statement: Proxy Filing

Sep 18, 2024, 7:00 AM EDT - 1 year ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings release: Q2 2024

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Jun 27, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Jun 12, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Quarterly report: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings release: Q1 2024

May 14, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

May 14, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Annual report: Q4 2023

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Mar 28, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Feb 6, 2024, 7:30 AM EST - 2 years ago

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Jan 8, 2024, 7:30 AM EST - 2 years ago

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Dec 11, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Nov 30, 2023, 7:00 AM EST - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Nov 29, 2023, 11:09 AM EST - 2 years ago

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Nov 29, 2023, 7:44 AM EST - 2 years ago

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Nov 29, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Nov 22, 2023, 7:00 AM EST - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 4:05 PM EST - 2 years ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Closes $4 Million Private Placement

Oct 26, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Reverse Stock Split

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Oct 5, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Oct 4, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

Loopi Jun. 6 at 10:18 AM

0 · Reply

kemsma62 Jun. 6 at 9:40 AM

$VVOS After a long period of decline, the stock is finally coming to life and attracting renewed investor interest.

0 · Reply

stockpicker12e Jun. 6 at 9:05 AM

0 · Reply

stockpicker12e Jun. 6 at 9:04 AM

0 · Reply

stockpicker12e Jun. 6 at 9:00 AM

0 · Reply

stockpicker12e Jun. 6 at 8:56 AM

$VVOS They have the bridge to cash flow positive. This is going to 100 dollars in time. This is like invisalign and better than inspire.

0 · Reply

Jerseyguy856 Jun. 6 at 2:55 AM

$VVOS left some on the table but made this in 1 min so cant complain

0 · Reply

skips200k Jun. 6 at 2:03 AM

$VVOS looking better. A few more strategic deals should do it. I think there's more in the works than we know. Glta.

0 · Reply

STACKD0E Jun. 6 at 1:12 AM

$ALL $VVOS

0 · Reply

ka1954 Jun. 5 at 10:49 PM

$VVOS why the after hours fuckery? we all know this is done for the near future

0 · Reply

AtackBrrr Jun. 5 at 10:42 PM

$VVOS BIG catalyst today 🔥 Company announced a $4.5M debt-to-equity exchange with senior lender Streeterville Capital. This helps clean up the balance sheet and directly supports Nasdaq listing compliance — one of the biggest overhangs on the stock. Also important: 👉 Debt repayment calls suspended for 90 days 👉 Securities sales restricted for 60 days That’s real near-term breathing room + reduced pressure on liquidity. Market already reacting strongly with heavy volume + momentum spike on the news. This is the kind of restructuring PR that can re-rate a beaten-down microcap when sentiment flips. Watching how it holds above $1 — momentum can push this further if volume stays hot. Not financial advice.

0 · Reply

AtackBrrr Jun. 5 at 10:38 PM

$VVOS I’ve been in this stock for a few years now. Historically, the most explosive moves tend to happen in after-hours trading. Last year it ran up to around $7, but I don’t think we see those levels again without significant new catalysts. That said, I do think a move toward $1.50–$2 is still realistic if momentum and news line up.

0 · Reply

Elevate1 Jun. 5 at 10:33 PM

$VVOS

0 · Reply

PiviotPoint Jun. 5 at 10:31 PM

$VVOS back to a dollar we go slap that bitch

0 · Reply

Elevate1 Jun. 5 at 10:30 PM

$VVOS As I posted earlier sleep apnea is the one agglomeration of every disease impacted by chronic oxidative and nitrosative stress. By the way this is 90% of all IS healthcare spending according to the CDC! If you have hypoxia( the real sleep apnea disease name)it either accentuates or is caused by chronic oxidative or nitrosative stress! This makes VVOS’s 3000 new patients a month and growing the most valuable patients in the US to the pharma and nutraceutical companies. The numbers are huge. The world will begin to see this from this day forward! Going up as the shorts learn first! I am long and will trade at will!

0 · Reply

tradesnap Jun. 5 at 10:24 PM

$VVOS 🚨 SnapScore™ 97/100 alert on $VVOS at 11:50 AM ET → $1.0801. HOD: $1.36 (+25.9% from alert) SnapScore™ alerts helped wrap up another 💰💰 week at TradeSnap!

0 · Reply